Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 05 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 21 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.